Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: From binding promiscuity to selective inhibition

Chemistry and Biology

Volumn 10, Issue 4, 2003, Pages 341-349

  Bencharit, Sompop ^a,b   Morton, Christopher L ^d   Hyatt, Janice L ^d   Kuhn, Peter ^e,f   Danks, Mary K ^d   Potter, Philip M ^d   Redinbo, Matthew R ^a,c  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e SLAC NATIONAL ACCELERATOR LABORATORY   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TORPEDO CALIFORNICA;

EID: 0345373886     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(03)00071-1     Document Type: Article

References (56)

1. Wadkins R.M., Morton C.L., Weeks J.K., Oliver L., Weirdl M., Danks M.K., Potter P.M. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol. Pharmacol. 60:2001;355-362.
2. Satoh T., Hosokawa M. The mammalian carboxylesterases. from molecules to functions Annu. Rev. Pharmacol. Toxicol. 38:1998;257-288.
3. Harrison E.H. Lipases and carboxylesterases. possible roles in the hepatic metabolism of retinol Annu. Rev. Nutr. 18:1998;259-276.
4. Satoh T., Taylor P., Bosron W.F., Sanghani S.P., Hosokawa M., La Du B.N. Current progress on esterases. from molecular structure to function Drug Metab. Dispos. 30:2002;488-493.
5. Kamendulis L.M., Brzezinski M.R., Pindel E.V., Bosron W.F., Dean R.A. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther. 279:1996;713-717.
6. Zhang J., Burnell J.C., Dumaual N., Bosron W.F. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J. Pharmacol. Exp. Ther. 290:1999;314-318.
7. Alexson S.E., Diczfalusy M., Halldin M., Swedmark S. Involvement of liver carboxylesterases in the in vitro metabolism of lidocaine. Drug Metab. Dispos. 30:2002;643-647.
8. Tang B.K., Kalow W. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. Eur. J. Clin. Pharmacol. 47:1995;449-451.
9. Takai S., Matsuda A., Usami Y., Adachi T., Sugiyama T., Katagiri Y., Tatematsu M., Hirano K. Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol. Pharm. Bull. 20:1997;869-873.
10. Bencharit S., Morton C.L., Xue Y., Potter P.M., Redinbo M.R. Structural basis of cocaine and heroin metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol. in press:2003.
11. Brzezinski M.R., Spink B.J., Dean R.A., Berkman C.E., Cashman J.R., Bosron W.F. Human liver carboxylesterase hCE-1. binding specificity for cocaine, heroin, and their metabolites and analogs Drug Metab. Dispos. 25:1997;1089-1096.
12. Brzezinski M.R., Abraham T.R., Stone C.L., Dean R.A., Bosron W.F. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem. Pharmacol. 48:1994;1747-1755.
13. Diczfalusy M.A., Bjorkhem I., Einarsson C., Hillebrant C.G., Alexson S.E. Characterization of enzymes involved in formation of ethyl esters of long-chain fatty acids in humans. J. Lipid Res. 42:2001;1025-1032.
14. Nanji A.A., Su G.L., Laposata M., French S.W. Pathogenesis of alcoholic liver disease-recent advances. Alcohol. Clin. Exp. Res. 26:2002;731-736.
15. Becker A., Bottcher A., Lackner K.J., Fehringer P., Notka F., Aslanidis C., Schmitz G. Purification, cloning, and expression of a human enzyme with acyl coenzyme A. cholesterol acyltransferase activity, which is identical to liver carboxylesterase Arterioscler. Thromb. 14:1994;1346-1355.
16. Ghosh S. Cholesteryl ester hydrolase in human monocyte/macrophage. cloning, sequencing, and expression of full-length cDNA Physiol. Genomics. 2:2000;1-8.
17. Mesange F., Sebbar M., Capdevielle J., Guillemot J.C., Ferrara P., Bayard F., Poirot M., Faye J.C. Identification of two tamoxifen target proteins by photolabeling with 4-(2-morpholinoethoxy)benzophenone. Bioconjug. Chem. 13:2002;766-772.
18. Ellgaard L., Molinari M., Helenius A. Setting the standards. quality control in the secretory pathway Science. 286:1999;1882-1888.
19. Potter P.M., Wolverton J.S., Morton C.L., Wierdl M., Danks M.K. Cellular localization domains of a rabbit and a human carboxylesterase. influence on irinotecan (CPT-11) metabolism by the rabbit enzyme Cancer Res. 58:1998;3627-3632.
20. van Pelt J.F., Moshage H.J., Depla E., Verhave J.P., Yap S.H. Identification of human liver carboxylesterase as one of the proteins involved in Plasmodium falciparum malaria sporozoite invasion in primary cultures of human hepatocytes. J. Hepatol. 27:1997;688-698.
21. Zhen L., Rusiniak M.E., Swank R.T. The beta-glucuronidase propeptide contains a serpin-related octamer necessary for complex formation with egasyn esterase and for retention within the endoplasmic reticulum. J. Biol. Chem. 270:1995;11912-11920.
22. Yue C.C., Muller-Greven J., Dailey P., Lozanski G., Anderson V., Macintyre S. Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum. J. Biol. Chem. 271:1996;22245-22250.
23. Labarrere C.A., Lee J.B., Nelson D.R., Al-Hassani M., Miller S.J., Pitts D.E. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease. a prospective study Lancet. 360:2002;1462-1467.
24. Jann M.W., Shirley K.L., Small G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41:2002;719-739.
25. Dvir H., Wong D.M., Harel M., Barril X., Orozco M., Luque F.J., Munoz-Torrero D., Camps P., Rosenberry T.L., Silman I.et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution. kinetic and molecular dynamic correlates Biochemistry. 41:2002;2970-2981.
26. Dvir H., Jiang H.L., Wong D.M., Harel M., Chetrit M., He X.C., Jin G.Y., Yu G.L., Tang X.C., Silman I.et al. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine a and (-)-huperzine B. structural evidence for an active site rearrangement Biochemistry. 41:2002;10810-10818.
27. Sjogren M., Hesse C., Basun H., Kol G., Thostrup H., Kilander L., Marcusson J., Edman A., Wallin A., Karlsson I.et al. Tacrine and rate of progression in Alzheimer's disease - relation to ApoE allele genotype. J. Neural Transm. 108:2001;451-458.
28. Tsolaki M., Pantazi T., Kazis A. Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease. a retrospective, longitudinal study J. Int. Med. Res. 29:2001;28-36.
29. Sussman J.L., Harel M., Silman I. Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs. Chem. Biol. Interact. 87:1993;187-197.
30. Harel M., Schalk I., Ehret-Sabatier L., Bouet F., Goeldner M., Hirth C., Axelsen P.H., Silman I., Sussman J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. USA. 90:1993;9031-9035.
31. Diller D.J., Pohl E., Redinbo M.R., Hovey B.T., Hol W.G. A rapid method for positioning small flexible molecules, nucleic acids, and large protein fragments in experimental electron density maps. Proteins. 36:1999;512-525.
32. Gilson M.K., Straatsma T.P., McCammon J.A., Ripoll D.R., Faerman C.H., Axelsen P.H., Silman I., Sussman J.L. Open "back door" in a molecular dynamics simulation of acetylcholinesterase. Science. 63:1994;1276-1278.
33. Bartolucci C., Perola E., Cellai L., Brufani M., Lamba D. "Back door" opening implied by the crystal structure of a carbamoylated acetylcholinesterase. Biochemistry. 38:1999;5714-5719.
34. Mulder M., Blokland A., van den Berg D.J., Schulten H., Bakker A.H., Terwel D., Honig W., de Kloet E.R., Havekes L.M., Steinbusch H.W.et al. Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. Lab Invest. 81:2001;953-960.
35. Camps P., Munoz-Torrero D. Tacrine-huperzine A hybrids (huprines). a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease Mini. Rev. Med. Chem. 1:2001;163-174.
36. Hu M.K., Wu L.J., Hsiao G., Yen M.H. Homodimeric tacrine congeners as acetylcholinesterase inhibitors. J. Med. Chem. 45:2002;2277-2282.
37. de los Rios C., Marco J.L., Carreiras M.D., Chinchon P.M., Garcia A.G., Villarroya M. Novel tacrine derivatives that block neuronal calcium channels. Bioorg. Med. Chem. 10:2002;2077-2088.
38. Carlier P.R., Chow E.S.-H., Han Y., Liu J., Yazal J.E., Pang Y.-P. Heterodimeric tacrine-based acetycholinesterase inhibitors. investigating ligand-peripheral site interaction J. Med. Chem. 42:1999;4225-4231.
39. Williams P.A., Cosme J., Sridhar V., Johnson E.F., McRee D.E. Mammalian microsomal cytochrome P450 monooxygenase. structural adaptations for membrane binding and functional diversity Mol. Cell. 5:2000;121-131.
40. Watkins R.E., Wisely G.B., Moore L.B., Collins J.L., Lambert M.H., Williams S.P., Willson T.M., Kliewer S.A., Redinbo M.R. The human nuclear xenobiotic receptor PXR. structural determinants of directed promiscuity Science. 292:2001;2329-2333.
41. Schumacher M.A., Miller M.C., Grkovic S., Brown M.H., Skurray R.A., Brennan R.G. Structural mechanisms of QacR induction and multidrug recognition. Science. 294:2001;2158-2163.
42. Morton C.L., Potter P.M. Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression. Application to a rabbit liver carboxylesterase. Mol. Biotechnol. 16:2000;193-202.
43. Danks M.K., Morton C.L., Krull E.J., Cheshire P.J., Richmond L.B., Naeve C.W., Pawlik C.A., Houghton P.J., Potter P.M. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin. Cancer Res. 5:1999;917-924.
44. Otwinowski Z., Minor W. Data Collection and Processing. 1993;Daresbury Laboratories, Warrington, United Kingdom.
45. Navaza J. AmoRe. an automated package for molecular replacement Acta Crystallogr. A. 50:1994;157-163.
46. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography and NMR system. a new software suite for macromolecular structure determination Acta Crystallogr. D. 54:1998;905-921.
47. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
48. Read R.J. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr. A. 42:1986;140-149.
49. Kraulis P.J. Molscript. a program to produce both detailed and schematic plots of protein structures J. Appl. Crystollogr. 24:1991;946-950.
50. Esnouf R.M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr. D. 55:1999;938-940.
51. Merritt E.A., Murphy M.E.P. Raster3D version 2.0-a program for photorealistic molecular graphics. Acta Crystallogr. D. 50:1991;869-873.
52. Beaufay H., Amar-Costesec A., Feytmans E., Thines-Sempoux D., Wibo M., Robbi M., Berthet J. Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods. J. Cell Biol. 61:1974;188-200.
53. Potter P.M., Wolverton J.S., Morton C.L., Wierdl M., Danks M.K. Cellular localization domains of a rabbit and a human carboxylesterase. influence on irinotecan (CPT-11) metabolism by the rabbit enzyme Cancer Res. 58:1998;3627-3632.
54. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
55. Ellman G.L., Courtney K.D., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
56. Doctor B.P., Toker L., Roth E., Silman I. Microtiter assay for acetylcholinesterase. Anal. Biochem. 166:1987;399-403.